1
|
The advantage of early liver transplantation for Wilson's disease using living donors. PRZEGLAD GASTROENTEROLOGICZNY 2021; 16:213-218. [PMID: 34584582 PMCID: PMC8456762 DOI: 10.5114/pg.2021.108990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 10/12/2020] [Indexed: 11/17/2022]
Abstract
Aim The aim of the study was to investigate the surgical timing, results, and advantages of living-donor liver transplantation in patients who underwent liver transplantation due to Wilson’s disease. Material and methods The study included Wilson’s patients who underwent liver transplantation and their live donors. Demographic information, preparations for surgery, liver transplant type, grafts used, results, and complications were examined. Results Between 2006 and 2020, 29 liver transplants were performed for 27 Wilson’s patients in our clinic. The study included 11 female and 16 male patients, with a mean age of 20.8 ±11.1 years and a mean body mass index of 20.5 ±3.2 kg/m2. The mean MELD score of the adult patients was 16.5 ±6.3, and the mean PELD score of the paediatric patients was 19.6 ±17.2. Five patients underwent transplantation due to acute liver failure, and 22 patients with low MELD score had liver transplants due to chronic liver disease. Three patients who were referred with acute liver failure died in the perioperative period; no mortality was observed in the 22 elective patients. The overall survival was calculated as 88.8%. The 1-, 3-, and 5-year survival were 100% among elective early transplanted patients. Conclusions Liver transplant is the most effective treatment for liver failure caused by Wilson’ s disease. When performed promptly, living-donor liver transplantation results in high survival rates in cases of both acute liver failure and chronic liver failure, and it no deterioration of the patient’s condition is evident.
Collapse
|
2
|
Lau NS, Jacques A, McCaughan G, Crawford M, Liu K, Pulitano C. Addressing the challenges of split liver transplantation through technical advances. A systematic review. Transplant Rev (Orlando) 2021; 35:100627. [PMID: 34052472 DOI: 10.1016/j.trre.2021.100627] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2021] [Revised: 04/08/2021] [Accepted: 05/17/2021] [Indexed: 12/16/2022]
Abstract
BACKGROUND Split liver transplantation addresses donor shortages by facilitating the transplant of two recipients using one donor liver. Some still consider these grafts inferior due to prolonged cold ischaemia time and at times difficult vascular reconstruction. Techniques such as in-situ splitting, machine perfusion and interposition grafts may address these challenges and thereby address these concerns. The aim of this review is to assess these technical advances in split liver transplantation, their utility and outcomes. METHODS A systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Keywords included 'split liver transplantation', 'arterial reconstruction', and 'machine perfusion'. Data found was synthesised into sections including: methods of splitting, full-left full-right splitting, donor cholangiography, machine perfusion and arterial reconstruction. RESULTS A total of 78 articles met inclusion criteria after screening of 151 eligible articles. These were subdivided into the following categories: in-situ (25), ex-vivo (25), full-left full-right splitting (15), donor cholangiography (2), machine perfusion (6), and arterial reconstruction (5). The in-situ splitting technique reduces the cold ischaemia time compared to the ex-vivo technique which may improve graft quality and liver splitting during normothermic machine perfusion is a novel technique with the potential to incorporate the best aspects of both techniques. Interposition grafts are often required during split liver transplantation but have an increased risk of hepatic artery thrombosis. CONCLUSION Advancements in technique have allowed many of the unique challenges of split liver transplantation to be overcome. Overall, this supports the use of split liver transplantation in broader and riskier settings and we advocate for liver transplant surgeons to not hesitate in using these grafts liberally and expanding their recipient selection criteria.
Collapse
Affiliation(s)
- Ngee-Soon Lau
- Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Sydney, New South Wales 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Andrew Jacques
- Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Sydney, New South Wales 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Geoffrey McCaughan
- Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Sydney, New South Wales 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Michael Crawford
- Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Sydney, New South Wales 2050, Australia
| | - Ken Liu
- Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Sydney, New South Wales 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Carlo Pulitano
- Australian National Liver Transplantation Unit, Royal Prince Alfred Hospital, Sydney, New South Wales 2050, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia.
| |
Collapse
|
3
|
Fakhar N, Nikeghbalian S, Kazemi K, Shamsayeefar AR, Gholami S, Kasraianfard A, Malek-Hosseini SA. Transplantation of Deceased Donor Livers With Elevated Levels of Serum Transaminases at Shiraz Transplant Center. HEPATITIS MONTHLY 2016; 16:e40140. [PMID: 27882068 PMCID: PMC5116126 DOI: 10.5812/hepatmon.40140] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/06/2016] [Revised: 08/14/2016] [Accepted: 09/27/2016] [Indexed: 12/11/2022]
Abstract
BACKGROUND The current organ shortage has prompted the use of marginal organs. We conducted this retrospective study to present our experience with transplanting deceased donor livers with elevated levels of serum transaminases and to explain whether elevated levels of serum transaminases in donors affect allograft function and survival of the recipients. METHODS Data of deceased donor livers and patients, who underwent liver transplantation from March 2013 to March 2015 at Shiraz center for organ transplantation, was reviewed. Liver donors with aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level of more than 500 IU/l and their related recipients were considered as the case group (n = 24) and the others were considered as the control group (n = 834). RESULTS In the case group, the medians of levels of serum AST and ALT of donors were 834 ± 425 IU/L (range: 250 - 2285) and 507 ± 367 IU/L (range: 100 - 1600), respectively. Recipients were followed for a median of 13.6 ± 9 months (range: 7 - 28.4). Post-transplant complications were acute rejection (n = 5), infection (n = 3), portal vein thrombosis (n = 3), bile duct stricture (n = 1), and hepatic artery stenosis (n = 1). The one-year survival rate of the patients was 91.7%. Demographics, post-transplant complications and one-year survival rates were not significantly different between the two study groups. CONCLUSIONS Transplanting deceased donor livers with markedly elevated liver enzymes may be an acceptable choice for expanding the donor pool.
Collapse
Affiliation(s)
- Nasir Fakhar
- Department of Surgery, Shiraz Center for Organ Transplantation, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Saman Nikeghbalian
- Department of Surgery, Shiraz Center for Organ Transplantation, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Kourosh Kazemi
- Department of Surgery, Shiraz Center for Organ Transplantation, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Ali Reza Shamsayeefar
- Department of Surgery, Shiraz Center for Organ Transplantation, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Siavash Gholami
- Department of Surgery, Shiraz Center for Organ Transplantation, Shiraz University of Medical Sciences, Shiraz, IR Iran
| | - Amir Kasraianfard
- Department of Surgery, Hamadan University of Medical Sciences, Hamadan, IR Iran
- Corresponding Author: Amir Kasraianfard, Besat Hospital, Hamadan University of Medical Sciences, Hamadan, IR Iran. Tel: +98-9123175338, E-mail:
| | - Seyed Ali Malek-Hosseini
- Department of Surgery, Shiraz Center for Organ Transplantation, Shiraz University of Medical Sciences, Shiraz, IR Iran
| |
Collapse
|
4
|
Nikeghbalian S, Aliakbarian M, Kazemi K, Shamsaee far A, Salehipour M, Bahreini A, Mehdi SH, Salahi H, Bahador A, Malekhosseini SA. Clinical Experience in Organ Transplant From The Shiraz Transplant Center: 2011. EXP CLIN TRANSPLANT 2012; 10:307-9. [DOI: 10.6002/ect.2012.0121] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
5
|
Farjam M, Dehdab P, Abbassnia F, Mehrabani D, Tanideh N, Pakbaz S, Imanieh MH. Thioacetamide-induced acute hepatic encephalopathy in rat: behavioral, biochemical and histological changes. IRANIAN RED CRESCENT MEDICAL JOURNAL 2012; 14:164-70. [PMID: 22737573 PMCID: PMC3372030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2011] [Accepted: 01/10/2012] [Indexed: 11/04/2022]
Abstract
BACKGROUND As a serious neuropsychiatric disease, hepatic encephalopathy (HE) is a clinical condition with several types regarding chronicity and clinical diversity that can develop as a complication of both acute and chronic liver failure. This study evaluates changes in thioacetamide (TAA)-induced acute hepatic encephalopathy (AHE) in rat as an animal model. METHODS Both genders of C57BL6, BALB/C mice and Sprague Dawley rats; (10 animals in each group) were compared for induction of AHE to clarify which animal and gender were appropriate. The animals (10 male rats in each group) were categorized in 4 groups according to the dose of the TAA administered (200, 300 and 400 mg/kg of TAA at 24 h intervals for 4 days). A control group was treated with solvent of TAA which was water (5 ml/kg/day). The behavioral, biochemical markers of hepatic failure and histological aspects of thioacetamide (TAA) induced AHE and the correlation between the clinical severity and liver failure biomarkers were evaluated. RESULTS Rat was shown to be an animal model of choice for AHE while the optimum dosage of TAA to induce AHE was 300 mg/kg/day at 24 h intervals for 4 days. The behavioral score was partially correlated with the rising of some biomarkers and pathological findings. CONCLUSION Rat can be introduced as the animal of choice for AHE to study the pathophysiology, pharmacology and the survival rate of disease in liver transplant patients.
Collapse
Affiliation(s)
- M Farjam
- Department of Pharmacology, Shiraz University of Medical Sciences, Shiraz, Iran
| | - P Dehdab
- Fars Science Research Branch, Islamic Azad University, Shiraz, Iran
| | - F Abbassnia
- Fars Science Research Branch, Islamic Azad University, Shiraz, Iran
| | - D Mehrabani
- Stem Cell Research and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran,Correspondence: Davood Mehrabani, PhD, Assistant Professor of Stem Cell Research and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Tel.: +98-711-2279711, Fax: +98-711-2279711, E-mail:
| | - N Tanideh
- Department of Pharmacology, Shiraz University of Medical Sciences, Shiraz, Iran,Stem Cell Research and Transgenic Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| | - S Pakbaz
- Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
| | - M H Imanieh
- Department of Pediatrics, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
| |
Collapse
|